Sign in
Taking people in United StatesPhase 1/2

Combined drug and radiation treatment study for locally advanced bladder cancer

Tests enfortumab vedotin plus radiation in adults with advanced bladder cancer.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
Status
Recruiting
Phase
Phase 1/2
People taking part
41 people, planned
Started
10 Oct 2024
Expected to end
24 Sept 2027
Type of study
Interventional
Treatments tested
  • Enfortumab Vedotin
  • Radiation Therapy
Record updated
15 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with bladder cancer (urothelial carcinoma) that has spread locally, who can have radiation treatment aimed at the disease.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Urothelial carcinoma of the bladder, confirmed by tissue testing, including T4N0 and T1-4N2-3 disease; mixed urothelial carcinoma is also included. Spread beyond the lymph nodes must be treatable in a radiation field.
Earlier treatment
No earlier radiation to the pelvis. No ongoing side effects of Grade 2 or higher (except hair loss) from earlier drug treatment. A prior stem cell or solid organ transplant is not allowed.

Main reasons for not taking part

  • Earlier radiation therapy to the pelvis
  • Known HIV infection, known hepatitis B, or known active hepatitis C
  • Active scleroderma, lupus, ulcerative colitis or similar disease that makes radiation unsafe
  • Pregnant, or expecting to conceive during the trial
  • Life expectancy under 12 weeks

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Pathologically confirmed diagnosis of urothelial carcinoma of the bladder including patients with T4N0 and T1-4N2-3 disease. Participants with mixed urothelial carcinoma of bladder will also be included
  • Be ≥ 18 years of age on the day of signing informed consent
  • ECOG performance status 0-2. NOTE: If participants is unable to walk due to paralysis, but is mobile in a wheelchair, participants is ambulatory for the purpose of assessing their performance status
  • The participant has the following baseline laboratory data:; Hemoglobin ≥ 9 g/dL; Platelet count ≥ 100 x 109 g/dL; Creatinine clearance (CrCl) ≥ 30 mL/min as estimated per institutional standards (glomerular filtration rate [GFR] can also be used instead of CrCl); Absolute neutrophil count (ANC) ≥ 1500/mm3
  • Male participants must consistently use highly effective methods of birth control starting at screening and continue throughout study period and for at least 6 months after radiation completion
  • Female participants must consistently use highly effective methods of birth control starting at screening and continue throughout the study period and for at least 6 months after radiation completion
  • Candidate for definitive local therapy to active disease per the discretion of the treating physicians

Who cannot take part

  • Has history of prior pelvic radiation therapy
  • Has ongoing clinically significant toxicity (Grade 2 or higher with exception of alopecia) associated with prior systemic therapy
  • Participants receiving ongoing systemic intravenous antimicrobial treatment for active infection at time of randomization
  • Has received a prior allogeneic stem cell or solid organ transplant
  • Has active tuberculosis As the CORe system in MDACC is set up as a one-step enrollment process, the above inclusion criteria will be assessed prior to CORe enrollment. Following CORe enrollment, the below exclusion criteria will be assessed
  • Has a diagnosis of active scleroderma, lupus, ulcerative colitis, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial as determined by the treating physician and/or member of the study team
  • Distant metastatic disease beyond lymph node metastases, which by the discretion of the treating physician cannot be treated definitively in a radiation field
  • Participants have a known history of hepatitis B (defined as HBsAg reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. No testing for hepatitis B and hepatitis C is required unless mandated by local health authority
  • Has a known history of human immunodeficiency virus (HIV) infection. Testing is not required unless mandated by the local health authority
  • Has conditions requiring high doses of steroids (>10 mg/day of prednisone or equivalent) or other immunosuppressive medications are excluded. Inhaled or topical steroids are permitted in the absence of active autoimmune disease. Physiologic replacement doses of corticosteroids are permitted for participants with adrenal insufficiency
  • Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
  • History of uncontrolled diabetes mellitus within 3 months of enrollment. Uncontrolled diabetes is defined as hemoglobin A1c (HbA1c) ≥ 8% or HbA1c between 7 and < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained
  • Female participants of childbearing potential should have a negative urine or serum pregnancy within 6 weeks prior to study registration up to the first fraction of radiation
  • Note: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Has estimated life expectancy of less than 12 weeks
  • Has preexisting sensory or motor neuropathy Grade ≥ 2
  • Is pregnant or expecting to conceive within the projected duration of the trial at the screening visit

Where in United States

  • MD Anderson Cancer CenterHouston, United StatesContact: Comron Hassanzadeh, MDTaking people

About the trial

What the trial wants to find out

To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.

The group in the trial

  • Enfortumab Vedotin with RadiationTreatment being tested

    Particpants will receive enfortumab vedotin by vein over about 1-2 hours on Days 1 and 8 of every 28-day cycle. Two dose levels of enfortumab vedotin will be tested. The dose of enfortumab vedotin participants receive will depend on when the participant join the study. Participants will also receive radiation therapy 5 times a week (Monday through Friday) for about 4-5 weeks.

    Treatment: Enfortumab Vedotin and Radiation Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
Plain-language title
Combined drug and radiation treatment study for locally advanced bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 June 2026